Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Payables (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Payables for 14 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables fell 71.64% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Dec 2025, down 71.64%, and an annual FY2025 reading of $2.7 million, down 71.64% over the prior year.
  • Payables was $2.7 million for Q4 2025 at Fate Therapeutics, down from $3.5 million in the prior quarter.
  • Across five years, Payables topped out at $11.4 million in Q1 2022 and bottomed at $2.7 million in Q4 2025.
  • Average Payables over 5 years is $6.9 million, with a median of $6.6 million recorded in 2021.
  • The sharpest move saw Payables soared 98.45% in 2024, then plummeted 71.64% in 2025.
  • Year by year, Payables stood at $8.6 million in 2021, then dropped by 4.03% to $8.3 million in 2022, then crashed by 42.9% to $4.7 million in 2023, then surged by 98.45% to $9.4 million in 2024, then tumbled by 71.64% to $2.7 million in 2025.
  • Business Quant data shows Payables for FATE at $2.7 million in Q4 2025, $3.5 million in Q3 2025, and $4.0 million in Q2 2025.